반응식
[CH3:1][O:2][C:3]1[CH:8]=[C:7]([CH3:9])[C:6]([S:10]([N:13]([CH2:15][C:16]2[O:20][N:19]=[C:18]([C:21](OCC)=[O:22])[N:17]=2)[CH3:14])(=[O:12])=[O:11])=[C:5]([CH3:26])[CH:4]=1.[N:27]1([CH2:32][CH2:33][CH2:34][N:35]2[CH2:40][CH2:39][NH:38][CH2:37][CH2:36]2)[CH2:31][CH2:30][CH2:29][CH2:28]1.C[Al](C)C>ClCCCl>[CH3:1][O:2][C:3]1[CH:4]=[C:5]([CH3:26])[C:6]([S:10]([N:13]([CH3:14])[CH2:15][C:16]2[O:20][N:19]=[C:18]([C:21]([N:38]3[CH2:37][CH2:36][N:35]([CH2:34][CH2:33][CH2:32][N:27]4[CH2:28][CH2:29][CH2:30][CH2:31]4)[CH2:40][CH2:39]3)=[O:22])[N:17]=2)(=[O:12])=[O:11])=[C:7]([CH3:9])[CH:8]=1참가 물질
5
반응물 3
생성물 1
시약·촉매·용매 1
실험 절차
The title compound was prepared according to general procedure AT using ethyl 5-({[(4-methoxy-2,6-dimethylphenyl)sulfonyl](methyl)amino}methyl)-1,2,4-oxadiazole-3-carboxylate (27 mg, 0.07 mmol), 1-[3-(pyrrolidin-1-yl)propyl]piperazine (40 mg, 0.20 mmol) and trimethylaluminium (2 M in toluene, 0.08 mL) in DCE (2 mL). A portion of the crude product was purified using prep method D.
후처리
- customA portion of the crude product was purified
출처 및 근거
- ORD 기록
- ord-3deb2db89e5c47fc9b9272b5b3a67b1c
- 출처 데이터셋
- uspto-grants-2014_01
- 특허 번호
- US08623859B2
연결된 노트
불러오는 중…